



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/804,763
Filing Date	March 19, 2004
First Named Inventor	QI, Yan
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	A-72186-1/TAL/DCF (471702-00008)

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RK	A1	5,242,687	09-07-1993	Tykocinski et al.	
RK	A2	5,601,828	02-11-1997	Tykocinski et al.	
RK	A3	5,623,056	04-22-1997	Tykocinski et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO 02/102852 A2/A3	12-27-2002	Avidex Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RK	C1	FINK, P., et al., "Haplotype-specific suppression of cytotoxic T cell induction by antigen inappropriately presented on T cells," <i>J. Exp. Med.</i> 157(1):141-154 (Jan. 1983).	
RK	C2	HAMBOR, J., et al., "CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8+ cells," <i>J. Immunol.</i> 145(6):1646-1652 (Sep. 1990).	
RK	C3	HAMBOR, J., et al., "Regulation of allogeneic responses by expression of CD8 α -chain of stimulator cells," <i>Int. Immunol.</i> 2(9):8856-8879 (1990).	
RK	C4	KAPLAN, D., et al., "An immunoregulatory function for the CD8 molecule," <i>Proc. Natl. Acad. Sci. USA</i> 86(21):8512-8515 (Nov. 1989).	
RK	C5	KRIEGER, N., et al., "CD4+ but not CD8+ cells are essential for alloreactivity," <i>J. Exp. Med.</i> 184(5):2013-2018 (Nov. 1996).	
RK	C6	QI, Y., et al., "Hybrid antibody mediated veto of cytotoxic T lymphocyte response," <i>J. Exp. Med.</i> 183(5):1973-1980 (May 1996).	
RK	C7	RAMMENSEE, H., et al., "Class I restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens," <i>J. Immunol.</i> 132(2):668-672 (Feb. 1984).	
RK	C8	RAMMENSEE, H., et al., "Suppression of cell-mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt-1+ and Lyt-2+ T cells of stimulator strain origin," <i>Eur. J. Immunol.</i> 12(11):930-934 (Nov. 1982).	
RK	C9	SAMBHARA, S., et al., "Programmed cell death of T cells signaled by the T cell receptor and the α -3 domain of class I MHC," <i>Science</i> 252(5011):1424-1427 (Jun. 1991).	
RK	C10	STAERZ, U., et al., "Treatment of an autoimmune disease with 'classical' T cell veto: a proposal," <i>J. Clin. Immunol.</i> 19(4):195-202 (Jul. 1999).	


Examiner Signature	/Robert Kelly/	Date Considered	08/28/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute PTO/SB/08A (08-03)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/804,763
				Filing Date	March 19, 2004
				First Named Inventor	QI, Yan
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	A-72186-1 [471702-00008]

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1					

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
RK	C1	MARTIN, P. J., "Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans," <i>J. Exp. Med.</i> 178(2):703-712 (Aug. 1993).		
RK	C2	WEISS, L., et al., "Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin," <i>Bone Marrow Transplant.</i> 23(11):1139-1143 (Jun. 1999).		


Examiner Signature	/Robert Kelly/	Date Considered	08/28/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	A-72186-1 [471702-00008]
-------	---	----	---	------------------------	--------------------------

Complete if Known

Application Number	10/804,763
Filing Date	March 19, 2004
First Named Inventor	Qi, Yan
Art Unit	1645
Examiner Name	To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RK	A1	5,078,998	01-07-1992	Bevan et al.	
RK	A2	6,060,054	05-09-2000	Staerz	
RK	A3	6,264,950 B1	07-24-2001	Staerz	
RK	A4	6,525,029 B1	02-25-1993	Falck-Pedersen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⁴
RK	B1	WO 90/10385 A1	09-20-1990	Tykocinski, Mark		
RK	B2	WO 96/32140 A1	10-17-1996	TKB Associates LP		
RK	B3	WO 99/23229 A1	05-14-1999	Cornell Res. Foundation, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁴
RK	C1	CONNOLLY, J., et al., "The Lyt-2 molecule recognizes residues in the class I $\alpha 3$ domain in allogeneic cytotoxic T cell responses," <i>J. Exp. Med.</i> 168(1):325-341 (Jul. 1988).	
RK	C2	KERN, P., et al., "Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8 $\alpha\alpha$ ectodomain fragment in complex with H-2K ^b ," <i>Immunity</i> 9(4):519-530 (Oct. 1998).	
RK	C3	POTTER, T., et al., "Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD7-dependent, but not CD8-independent, cytotoxic T lymphocytes," <i>Nature</i> 337(6202):73-75 (Jan. 1989).	
RK	C4	SALTER, R., et al., "A binding site for the T-cell co-receptor CD8 on the $\alpha 3$ domain of HLA-A2," <i>Nature</i> 345(6270):41-46 (May 1990).	
RK	C5	WOODLE, E., et al., "Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway," <i>J. Immunol.</i> 158(5):2156-2164 (Mar. 1997).	


Examiner Signature	/Robert Kelly/	Date Considered	08/28/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/804,763
		Filing Date	March 19, 2004
		First Named Inventor	QI, Yan
		Art Unit	1633
		Examiner Name	KELLY, Robert M
		Attorney Docket Number	A-72186-1 (471702-00008)
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RK	C1	GAME, D., et al., "Rejection mechanisms in transplantation," <i>Wien Klin. Wochenschr.</i> 113(20-21):823-838 (Oct. 2001).			
RK	C2	JOHNSON-SALIBA, M., et al., "Gene therapy: optimising DNA delivery to the nucleus," <i>Curr. Drug Targets</i> 2(4):371-399 (Dec. 2001).			
RK	C3	PFEIFER, A., et al., "Gene therapy: promises and problems," <i>Annu. Rev. Genomics Hum. Genet.</i> 2:177-211 (2001).			
RK	C4	SHOJI, Y., et al., "Current status of delivery systems to improve target efficacy of oligonucleotides," <i>Curr. Pharm. Des.</i> 10(7):785-796 (2004).			
RK	C5	VERMA, I., et al., "Gene therapy -- promises, problems and prospects," <i>Nature</i> 389(6648):239-242 (Sep. 1997).			

Examiner Signature	/Robert Kelly/	Date Considered	08/28/2006
--------------------	----------------	-----------------	------------

*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2